Search This Blog

Monday, June 14, 2021

Gilead Longer Data for Kite's Yescarta® inFollicular Lymphoma Shows Substantial Survival Improvement

 94% of Patients Achieved a Response at 18 Months in Pivotal ZUMA-5 Trial --

-- Yescarta Reduced Risk of Death by 58% Compared to Current Therapies in Weighted Analysis of ZUMA-5 Compared to SCHOLAR-5 External Control Cohort --

-- Late-breaking Data Presented at European Hematology Association (EHA) 2021 --

https://www.marketscreener.com/quote/stock/GILEAD-SCIENCES-INC-4876/news/Gilead-Sciences-nbsp-Longer-term-Data-for-Kite-s-Yescarta-in-Relapsed-or-Refractory-Follicular-Ly-35587447/

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)